GILEAD SCIENCES ($GILD) posted quarterly earnings results on Thursday, April 24th. The company reported earnings of $1.81 per share, beating estimates of $1.80 by $0.01. The company also reported revenue of $6,667,000,000, missing estimates of $6,905,472,124 by $-238,472,124.
You can see Quiver Quantitative's $GILD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
GILEAD SCIENCES Insider Trading Activity
GILEAD SCIENCES insiders have traded $GILD stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $GILD stock by insiders over the last 6 months:
- ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 11 sales selling 564,930 shares for an estimated $54,892,531.
- MERDAD PARSEY (Chief Medical Officer) has made 0 purchases and 7 sales selling 189,801 shares for an estimated $17,435,498.
- JEFFREY BLUESTONE sold 6,788 shares for an estimated $620,355
- JOHANNA MERCIER (Chief Commercial Officer) sold 5,000 shares for an estimated $456,400
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
GILEAD SCIENCES Hedge Fund Activity
We have seen 817 institutional investors add shares of GILEAD SCIENCES stock to their portfolio, and 856 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 10,487,673 shares (+145.1%) to their portfolio in Q4 2024, for an estimated $968,746,355
- FMR LLC added 7,157,113 shares (+21.6%) to their portfolio in Q4 2024, for an estimated $661,102,527
- PACER ADVISORS, INC. added 5,653,075 shares (+723.3%) to their portfolio in Q4 2024, for an estimated $522,174,537
- CAPITAL WORLD INVESTORS removed 4,842,566 shares (-6.3%) from their portfolio in Q4 2024, for an estimated $447,307,821
- AMUNDI removed 4,596,188 shares (-33.8%) from their portfolio in Q4 2024, for an estimated $424,549,885
- CAPITAL RESEARCH GLOBAL INVESTORS removed 3,853,443 shares (-6.2%) from their portfolio in Q4 2024, for an estimated $355,942,529
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 2,857,063 shares (-95.3%) from their portfolio in Q4 2024, for an estimated $263,906,909
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
GILEAD SCIENCES Government Contracts
We have seen $117,519 of award payments to $GILD over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- LENACAPAVIR TABS & INJECTIONS: $47,796
- LENACAPAVIR: $47,796
- SULENCA INJ: $14,937
- SUNLENCA 300MG TAB,PKT,5: $3,882
- SUNLENCA 300MG TAB,PKT,4: $3,105
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
GILEAD SCIENCES Congressional Stock Trading
Members of Congress have traded $GILD stock 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:
- REPRESENTATIVE JEFFERSON SHREVE purchased up to $50,000 on 03/31.
- REPRESENTATIVE CAROL D. MILLER purchased up to $15,000 on 03/10.
- REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 03/07.
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 12/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
GILEAD SCIENCES Analyst Ratings
Wall Street analysts have issued reports on $GILD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 03/11/2025
- Deutsche Bank issued a "Buy" rating on 02/18/2025
- Citigroup issued a "Buy" rating on 11/13/2024
To track analyst ratings and price targets for GILEAD SCIENCES, check out Quiver Quantitative's $GILD forecast page.
GILEAD SCIENCES Price Targets
Multiple analysts have issued price targets for $GILD recently. We have seen 5 analysts offer price targets for $GILD in the last 6 months, with a median target of $126.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $130.0 on 03/11/2025
- An analyst from Johnson Rice set a target price of $126.0 on 03/05/2025
- An analyst from Oppenheimer set a target price of $132.0 on 03/04/2025
- Brian Abrahams from RBC Capital set a target price of $83.0 on 01/07/2025
- Joseph Catanzaro from Piper Sandler set a target price of $105.0 on 11/07/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
